Ireland
News Category

Helus Pharma CEO to Present at H.C. Wainwright Conference, Highlighting Phase 3 Depression Drug
Helus Pharma's CEO participation in a major investment conference underscores the company's progress in developing novel treatments for depression and...

New Study Challenges Core Safety Assumption of Electroshock Therapy, Reigniting Calls for FDA Ban
A University of Houston study contradicts the long-held 'shunting theory' that ECT is safe, showing 82.5% of current flows through the brain, promptin...

Helus Pharma Appoints Key Executives to Bolster Leadership and Scientific Expertise
Helus Pharma announced the appointment of Regina Donohue as Chief People Officer and Dr. Suresh Durgam to its Scientific Advisory Board, signaling a s...

Helus Pharma Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data
Helus Pharma reports progress in its Phase 3 program for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and provides fina...

Helus Pharma Appoints Michael Halstead as CEO Amid Phase 3 Progress
Helus Pharma has named Michael Halstead as its new CEO, bringing extensive biopharmaceutical experience as the company advances its lead depression ca...

Luke Van Der Veer's Website Rental Coaching Program Expands Local SEO Training to 14 Countries
Website Rental Coaching, founded by Luke Van Der Veer, has expanded its local SEO training program to 14 countries, teaching entrepreneurs the 'Rank a...

Ireland Bans Electroshock Treatment on Minors, Advocates Push for Full Prohibition
Ireland has banned electroconvulsive therapy (ECT) for minors under its new Mental Health Act, a move hailed as a human rights advance, while advocate...

Helus Pharma Completes Enrollment in Phase 3 Depression Trial for HLP003
Helus Pharma has completed enrollment in its Phase 3 APPROACH trial for HLP003, a deuterated psilocin analogue for major depressive disorder, with res...

Helus Pharma Reports Fiscal 2026 Results, Phase 3 Depression Trial Enrollment Surpasses 88%
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...

Helus Pharma Closes $50 Million Public Offering to Advance Mental Health Pipeline
Helus Pharma has closed a $50 million underwritten public offering, with proceeds earmarked for clinical development of its novel serotonergic agonist...
Japan Creator Support Fund Reports International Breakthroughs Across Creative Industries
The Japan Creator Support Fund has generated tangible international outcomes including awards, nominations, and co-productions across music, film, gam...

Helus Pharma Prices $50 Million Public Offering to Advance Depression and Anxiety Programs
Helus Pharma has priced a $50 million public offering to fund Phase 3 trials for its depression treatment and other pipeline candidates.

